tirzepatide is the same as zepbound FDA approval for (tirzepatide) injection, first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Tirzepatide Zepbound® - Injectable -

Lilly has said they plan to submit the drug to the FDA for type 2 diabetes approval sometime in 2026

Found a 2.19 times higher risk of developing NAION for patients prescribed weekly semaglutide (Ozempic, Wegovy)

Dont put your health at risk chasing unproven solutions

This shift reflects a broader recognition that health interventions should be tailored to individual needs, genetic predispositions, and lifestyle factors

Retatrutide is the agonist of GLP-1 receptor, GIP receptor, and glucagon (GCG) receptor, which can reduce body weight and improve blood glucose by subcutaneous injection once a week(Rosenstock et al 2023)

The daily dosing schedule and gradual titration protocol may contribute to better gastrointestinal tolerance for some patients